Cipla Limited is one of India’s oldest and most respected pharmaceutical companies, recognized globally for expanding access to affordable medicines. Founded in 1935 by Dr. Khwaja Abdul Hamied, the company develops, manufactures, and markets prescription medicines, respiratory therapies, anti-infectives, cardiovascular drugs, oncology products, and consumer healthcare solutions. Cipla has built a strong international presence spanning more than 80 countries while maintaining leadership in the Indian pharmaceutical market. The company is particularly known for pioneering affordable HIV/AIDS treatments and continues to advance innovation across respiratory care, complex generics, inhalation therapies, and digital health. Cipla operates multiple manufacturing facilities that meet global regulatory standards, enabling reliable supply across developed and emerging markets. Guided by its purpose of “Caring for Life,” the company emphasizes patient-centric innovation, sustainability, and healthcare accessibility, making it one of the world’s leading generic pharmaceutical manufacturers and a trusted partner across global healthcare systems.
NSE: CIPLA | BSE: 500087
Mumbai, Maharashtra, India
